Memo Therapeutics AG is a clinical stage Biopharmaceutical company developing anti viral and cancer mAbs based on its proprietary best-in-class B-cell antibody repertoire copying technology. Its lead program is an anti-BK virus mAb in kidney transplantation.

TargED Biopharmaceuticals B.V. is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis. TargED stands for Targeted Enzyme Delivery.

Tridek One pursues development of immune checkpoint agonists

Step Pharma is developing novel therapeutics that inhibit the enzyme CTP Synthase 1 (CTPS1). Our most advanced programme is STP938 which is being developed as a targeted therapy for T-cell malignancies.Step Pharma was created on the basis of research on genetic immunodeficiencies led by Prof. Alain Fischer at the Imagine Institute (Paris, France) which established the essential role of CTPS1 in T- and B-cell proliferation.

A cleantech company delivering solutions and products to improve energy efficiency. The waste heat recovery systems for Flue gas and Exhaust air prevent corrosion and fouling problems, which limit heat recovery in the industry. Sold to Bos-Nieuwkerk

Developing the GAMMABODY™ PLATFORM to transform cancer therapy. Our Gammabody™ platform generates bispecific gamma delta T cell engagers that specifically activate a unique and relatively abundant effector gamma-delta T cell subset called Vγ9Vδ2 (Vgamma9 Vdelta2) T cells. This approach is designed to complement natural tumor recognition, direct Vγ9Vδ2 T cells to the tumor, selectively kill cancer cells and trigger an immune response cascade. Our Gammabody™ drug candidates have, in preclinical studies, demonstrated superior efficacy and safety profiles compared to other bispecific T cell engagers approaches in preclinical studies and show preferential activity against tumor cells thereby potentially limiting toxicity in healthy tissue. To date, we are the only company developing bispecific gamma delta T cell engaging antibodies for the treatment of cancer.

Lead Pharma is a spinoff from the prestigious Hubrecht Institute and the University Medical Center Utrecht. We develop innovative small-molecule therapies for patients with autoimmune disease or cancer.

IsoTis focuses on tissue engineering and biomaterial solutions for bone, cartilage and skin repair, as well as drug delivery.